Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a du...
Main Authors: | Roberta Sulsenti, Barbara Frossi, Lucia Bongiovanni, Valeria Cancila, Paola Ostano, Irene Fischetti, Claudia Enriquez, Francesca Guana, Giovanna Chiorino, Claudio Tripodo, Carlo E. Pucillo, Mario P. Colombo, Elena Jachetti |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.622001/full |
Similar Items
-
Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy
by: Roberta Sulsenti, et al.
Published: (2023-06-01) -
Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing
by: Jason R. Burchett, et al.
Published: (2022-09-01) -
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
by: Yi-Bo Hou, et al.
Published: (2019-08-01) -
Mast Cells Respond to Candida albicans Infections and Modulate Macrophages Phagocytosis of the Fungus
by: Marco De Zuani, et al.
Published: (2018-11-01) -
Editorial: Advances in mast cell physiology and mast cell-driven diseases
by: Ulrich Blank, et al.
Published: (2023-10-01)